StockNews.com Begins Coverage on Liberty TripAdvisor (NASDAQ:LTRPA)
by Kim Johansen · The Markets DailyStockNews.com assumed coverage on shares of Liberty TripAdvisor (NASDAQ:LTRPA – Free Report) in a report issued on Monday morning. The brokerage issued a buy rating on the technology company’s stock.
Liberty TripAdvisor Stock Performance
NASDAQ LTRPA opened at $0.50 on Monday. Liberty TripAdvisor has a fifty-two week low of $0.29 and a fifty-two week high of $1.95. The firm has a market capitalization of $38.66 million, a P/E ratio of -0.88 and a beta of 3.49. The stock’s fifty day moving average is $0.45 and its two-hundred day moving average is $0.49. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.08 and a current ratio of 1.08.
Liberty TripAdvisor (NASDAQ:LTRPA – Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The technology company reported $0.05 earnings per share (EPS) for the quarter. Liberty TripAdvisor had a negative net margin of 2.37% and a negative return on equity of 3.55%. The firm had revenue of $532.00 million during the quarter.
About Liberty TripAdvisor
Liberty TripAdvisor Holdings, Inc operates a travel guidance platform that connects people and audiences with travel partners in the United States, the United Kingdom, and internationally. The company operates in three segments: Brand Tripadvisor, Viator, and TheFork. It offers an online platform that provides content, travel guidance products and services, and two-sided marketplaces for travelers to discover, generate, and share authentic user-generated content in the form of ratings and reviews for destinations, points-of-interest, experiences, accommodations, restaurants, cruises, and other travel categories, including alternative accommodations, flights, and rental cars.
See Also
- Five stocks we like better than Liberty TripAdvisor
- The Basics of Support and Resistance
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- 2 Generic Drug Stocks Ready to Surge in 2025